喹硫平、阿立哌唑与氨磺必利治疗精神分裂症的疗效与安全性研究  

Efficacy and safety of quetiapine,aripiprazole and amisulpride in the treatment of schizophrenia

作　　者：张智勇[1] 谢玲银[1] 黄伟波 

机构地区：[1]清远市人民医院,广东清远511500 [2]清远市中医院,广东清远511500

出　　处：《实用药物与临床》2015年第9期1070-1072,共3页Practical Pharmacy and Clinical Remedies

基　　金：清远市科技计划项目(2014B032)

摘　　要：目的 研究喹硫平、阿立哌唑与氨磺必利治疗精神分裂症的疗效与安全性. 方法 选择2014年1-10月在我院精神科住院的300例精神分裂症患者,随机分为喹硫平组、阿立哌唑组、氨磺必利组,分别给予喹硫平[400～800 mg/d,平均（512 ±128）mg/d]、阿立哌唑[10～30 mg/d,平均（20 ±6）mg/d]、氨磺必利[400～800 mg/d,平均（635±147）mg/d]治疗8周. 于分组前及治疗后4、8周用评估阳性和阴性症状量表（PANSS）、不良反应量表（ TESS）评定疗效和不良反应,用社会功能量表（ PSP）评定患者的社会功能. 结果 喹硫平组总有效率为68. 4%,阿立哌唑组总有效率为70.0%,氨磺必利组总有效率为69. 6%,三组总有效率比较,差异无统计学意义（P〉0.05）;三组患者CGI评分及PSP评分均显著增加. 结论 喹硫平、阿立哌唑与氨磺必利治疗精神分裂症的疗效相当,但不良反应特点不同.Objective To study the antipsychotic efficacy and safety of three kinds of drugs on patients with schizophrenia. Methods Patients with schizophrenia in our hospital from January to October in 2014 were selected and randomly divided into three groups,quetiapine group （n=98）accepted quetiapine 400 ～800 （512 ± 128）mg/d,aripi-prazole group （n=100） accepted aripiprazole 10～30 （20 ±6） mg/d,amisulpride group （n=102） accepted amisul-pride 400～800（635 ± 147） mg/d respectively for eight weeks. The efficacy and adverse reactions were evaluated by PANSS and TESS,and the social function was evaluated by PSP before and after 4 and 8 weeks of treatment. Results The total effective rate of quetiapine group,aripiprazole group and amisulpride group was 68. 4%,70.0% and 69. 6%respectively,there was no significant difference among the three groups（P〉0.05）. The score of CGI and PSP of each group increased significantly. Conclusion Quetiapine,aripiprazole and amisulpride have similar efficiency in the treat-ment of schizophrenic patients,but the adverse reactions features are different.

关 键 词：抗精神病药 精神分裂症 疗效 安全性 

分 类 号：R749.3[医药卫生—神经病学与精神病学]